Joseph Carragher, DO
Interventional Cardiology · South Pasadena, FLNPI 1477988897
Payments from drug & device makers
Across 347 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$883
- Amgen$790
- Shockwave Medical, Inc$492
- Boston Scientific$428
- Cardiovascular Systems Inc.$415
- Novartis$405
- plus $4K from 36 others
What the payments were for
- Food & beverage$7,21795%
- Education$3985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 20 | $883 |
| Amgen | 50 | $790 |
| Shockwave Medical, Inc | 42 | $492 |
| Boston Scientific | 17 | $428 |
| Cardiovascular Systems Inc. | 19 | $415 |
| Novartis | 21 | $405 |
| AstraZeneca | 18 | $390 |
| Pfizer | 23 | $387 |
| Astellas Pharma US Inc | 6 | $329 |
| Endologix LLC | 5 | $305 |
| Johnson & Johnson | 13 | $255 |
| Merck | 12 | $239 |
| Boehringer Ingelheim | 13 | $238 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $186 |
| Novo Nordisk | 7 | $151 |
| E.r. Squibb & Sons, L.L.C. | 10 | $149 |
| Medtronic | 4 | $143 |
| Edwards Lifesciences | 6 | $140 |
| Inari Medical, Inc. | 3 | $137 |
| Abiomed | 5 | $134 |
| Osprey Medical Inc | 1 | $127 |
| Esperion Therapeutics, Inc. | 7 | $127 |
| Sanofi-aventis U.S. LLC | 4 | $89 |
| Amarin Pharma, Inc. | 4 | $89 |
| Actelion Pharmaceuticals US, Inc. | 4 | $80 |
| Medicure Pharma Inc. | 1 | $74 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Chiesi USA, Inc. | 3 | $43 |
| Angiodynamics, Inc. | 1 | $40 |
| Cvrx, Inc. | 1 | $35 |
| AbbVie | 1 | $32 |
| Terumo Medical Corporation | 2 | $30 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Reflow Medical Inc | 1 | $24 |
| Stryker | 1 | $22 |
| Philips North America LLC | 1 | $19 |
| Innovation Technologies Inc | 1 | $19 |
| Vital Connect, Inc | 1 | $18 |
| Biotronik Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,615 in reported general payments places this provider in the 40th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $81,962 |
| FarxigaDapagliflozin Propanediol | 45 | $47,795 |
| EntrestoSacubitril/Valsartan | 46 | $47,236 |
| BrilintaTicagrelor | 22 | $22,933 |
| JardianceEmpagliflozin | 14 | $15,600 |
| MultaqDronedarone Hcl | 11 | $13,616 |
| Repatha SyringeEvolocumab | 18 | $11,201 |
| Ranolazine ErRanolazine | 12 | $1,206 |
| Metoprolol Succinate | 77 | $773 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $676 |
| Ezetimibe | 36 | $652 |
| Carvedilol | 73 | $639 |
| Atorvastatin Calcium | 91 | $572 |
| Rosuvastatin Calcium | 62 | $447 |
| ClopidogrelClopidogrel Bisulfate | 46 | $370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $387 | $81,96271 claims |
| AstraZenecaFarxiga, Brilinta | $390 | $70,72867 claims |
| NovartisEntresto | $405 | $47,23646 claims |
| Boehringer IngelheimJardiance | $238 | $15,60014 claims |
| Sanofi-aventis U.S. LLCMultaq | $89 | $13,61611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in South Pasadena
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.